SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a strategic deal to repurchase a significant stake in its Ireland Fab 34 facility, a move that investors view as a major vote of confidence in the company's manufacturing turnaround and future AI chip demand. The community is actively debating the stock's potential for a broader recovery, with many traders closely monitoring price levels to see if the recent momentum can sustain a breakout above key resistance zones.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is maintaining strong momentum as the community rallies around its unique 'culture-first' brand identity ahead of key industry events. Investors are actively discussing its long-term potential, citing consistent organic growth and a commitment to advocacy that resonates with supporters beyond traditional market metrics.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending following a strategic partnership with Ukraine's Spetstechnoexport to advance multi-domain uncrewed systems and the acquisition of Apium Swarm Robotics, fueling community excitement around the company's expanding defense capabilities. Investors are actively debating the stock's potential as a key player in the drone sector, balancing enthusiasm for new NATO and defense contracts against concerns over share dilution and the need for more concrete revenue guidance.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is surging following the FDA approval of VYKAT XR, the first treatment for hyperphagia in Prader-Willi syndrome, fueling community discussion around its blockbuster potential and possible future acquisition. Investors are closely monitoring the stock's transition from a clinical-stage development play to a commercial-stage entity, with analysts aggressively revising price targets upward to reflect the de-risked profile.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as traders closely watch the stock's relative strength and consolidation patterns amid a broader market pullback. Market participants are actively discussing the impact of recent subscription price increases on revenue growth while monitoring key technical resistance levels that could trigger a potential breakout.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently experiencing intense volatility and downward pressure as investors grow increasingly frustrated with leadership's communication and the lack of a major partnership or buyout announcement. The community is actively debating the impact of recent R&D leadership changes and speculative proxy pressure, while many remain focused on the potential value of the Matrix-M platform to spark a significant recovery.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind $BUTTCOIN as a satirical movement aimed at disrupting the traditional financial system, with community members actively promoting it as the next major meme cycle. The conversation is driven by intense speculation and viral narratives, with supporters urging others to join the movement to flip Bitcoin while others emphasize the coin's role as a lighthearted commentary on market volatility.

ProShares Trust - ProShares K-1 Free Crude Oil ETF

ProShares K-1 Free Crude Oil Strategy ETF

ProShares K-1 Free Crude Oil Strategy ETF is attracting attention as the broader energy sector faces significant volatility driven by a growing global crude supply glut and shifting geopolitical dynamics, including potential ceasefire developments and diplomatic negotiations. Market participants are actively debating the sustainability of current oil price levels, with many community members focusing on technical indicators, inventory data, and the potential impact of geopolitical cooling on long-standing supply-shock narratives.

Satellogic, Inc. operates as a vertically integrated geospatial company. It is creating and continuously enhancing the first scalable, fully automated EO platform with the ability to remap the entire planet at both high-frequency and high-resolution, providing accessible and affordable solutions for customers. The company was founded by Emiliano Kargieman and Gerardo Richarte in July 2010 and is headquartered in Davidson, NC.

Satellogic Inc - Ordinary Shares - Class A

Satellogic is currently generating significant investor interest as it rides the momentum of the booming space sector, fueled by anticipation of a potential SpaceX IPO and increased demand for defense-related geospatial intelligence. The community is actively discussing the stock's long-term growth potential and recent technical price action, while monitoring key catalysts like upcoming industry symposiums, government contract developments, and the company's recent expansion of its satellite constellations.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased investor attention as a leading example of post-quantum cryptography in a recent Google research paper, bolstering the community's long-term thesis on its security standards. While some users are actively debating potential institutional utility and the impact of the foundation's shift to the U.S., community discussions remain heavily polarized between long-term proponents betting on technical robustness and critics focused on recent price trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

British drugmaker GSK Plc (GSK) on Wednesday announced that it now expects full-year earnings and turnover to be toward the top end of its guidance after its second-quarter earnings surpassed Wall Street expectations on strong sales of its specialty medicines.The company now <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf">expects</a> turnover growth to be toward the top end of 3% to 5% and for core earnings per share growth to be closer to 8% at constant exchange rate.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GSK">GSK</a> trended in the ‘bearish’ territory over the past 24 hours, while message volume dropped from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_8_18_14_AM_png_6f597ae2a0.webp" alt="GSK's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 30, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>GSK's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>CEO Emma Walmsley pegged the increase in guidance to another quarter of excellent performance, driven by the company’s specialty medicines segment.“We also continue to make very good progress in research and development, with 3 major FDA approvals achieved so far this year, 16 assets now in late-stage development, and 4 more promising medicines to treat cancer, liver disease and HIV expected to enter Phase III and pivotal development by the end of the year. With all this, we now expect to be towards the top end of our financial guidance for 2025 and remain confident in our long-term outlooks," the CEO said.GSK is eyeing annual sales of over £40 billion ($53.28 billion) by 2031. &nbsp;The company on Wednesday noted that its guidance is inclusive of tariffs enacted by the U.S. thus far and European tariffs indicated this week.“We are positioned to respond to the potential financial impact of tariffs, with mitigation options identified. Given the uncertain external environment, we will continue to monitor developments,” the firm said.For the second quarter, the company reported sales of about £8.00 billion, marking a growth of 6% at constant exchange rate and above an analyst estimate of £7.81 billion, according to data from Fiscal AI.Specialty medicines sales rose 15% to £3.3 billion, thanks to double-digit sales growth in Respiratory, Immunology &amp; Inflammation, Oncology, and HIV drugs at constant exchange rate.Vaccine sales, meanwhile, rose 9% to £2.1 billion while general medicines sales fell 6%.Core earnings per share came in at 46.5 pence in the three months through the end of June, up from an analyst estimate of 42 pence.NYSE-listed shares of GSK are up by over 11% this year but down by over 5% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/humana-announces-upbeat-earnings-raised-guidance/choXGmPR5zr">Humana Stock Gains On Upbeat Earnings And Raised Guidance, Draws Retail Praise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: £1= $1.33)

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’

GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate.

Equity

U.S. Food and Drug Administration reviewers on Tuesday flagged certain concerns about GSK Plc’s (GSK) investigational cancer drug called Blenrep, including a high rate of ocular toxicities.Ocular toxicity refers to the harmful effects a substance or drug has on the eye, potentially causing damage to its structure or impairing its function.<a href="https://stocktwits.com/symbol/GSK">GSK</a> is seeking approval for the drug, also known as Belantamab Mafodotin, in the treatment of adults with multiple myeloma in combination with Bortezomib or Pomalidomide and Dexamethasone in patients who have received at least one prior line of therapy. The application is based on data from two late-stage trials.FDA reviewers <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/media/187578/download">stated</a> in briefing documents on the regulator’s website that the benefit-risk profile of the drug for treating multiple myeloma “remains unclear,” considering efficacy results, safety and tolerability concerns, and uncertainties regarding the appropriateness of the proposed dosages.The documents were released ahead of an advisory committee meeting scheduled for Thursday. The FDA is expected to decide on approving or disapproving the drug by next week.The reviewers noted a high incidence of ocular toxicity with the treatment, including keratopathy (changes in the corneal epithelium), changes in clarity of vision, as well as other ocular symptoms, such as blurred vision and dry eyes.“The ocular toxicity, including corneal toxicity, observed with Belantamab Mafodotin is a unique toxicity that is not seen with any currently available treatments for multiple myeloma,” they said.While ocular toxicity may be asymptomatic in its early stages, it can result in severe consequences, such as loss of vision, the reviewers noted.The agency also expressed concern that the dosages of Belantamab Mafodotin have not been adequately optimized, as evidenced by the high rates of dose modifications in both trials referred to in the application.A majority of patients were not receiving the intended dosage and required frequent dose modifications, including interruptions, throughout the duration of treatment, the agency said.Blenrep was previously granted accelerated approval as monotherapy on Aug. 5, 2020, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least four prior therapies. It was subsequently withdrawn on Feb. 6, 2023, due to failure of the confirmatory trial to meet its progression-free survival endpoint.On Stocktwits, retail sentiment about GSK fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_15_at_1_26_26_PM_png_1594f6ef5c.webp" alt="GSK's Sentiment Meter and Message Volume as of 1:25 p.m. ET on July 15, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>GSK's Sentiment Meter and Message Volume as of 1:25 p.m. ET on July 15, 2025 | Source: Stocktwits</figcaption></figure>GSK stock is up 6% this year but down by 4% in the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-stock-flies-on-expansion-of-marina-site/ch8Q95jR5Fw">Joby Aviation Stock Flies High On Expansion Of Marina Site, Retail Boards The Flight</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

US FDA Reviewers Highlight Safety Concerns With GSK’s Investigational Cancer Drug: Retail’s On The Fence

FDA reviewers said in briefing documents that the benefit-risk profile of the drug for the treatment of multiple myeloma “remains unclear.”

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the disease has been accepted by the U.S. Food and Drug Administration (FDA).The vaccine is currently approved in the U.S. for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk. Adults can be at increased risk for RSV disease due to certain comorbidities, immune-compromised status, or advanced age.A regulatory decision by the FDA on this submission is <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/en-gb/media/press-releases/us-fda-accepts-application-to-review-expanded-use-of-gsk-s-rsv-vaccine/">expected</a> in the first half of 2026.<a href="https://stocktwits.com/symbol/GSK">GSK</a> is continuing to seek expanded indications for its RSV vaccine in other geographies, including in the European Economic Area and Japan, the company said.RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year, as per GSK. RSV can exacerbate conditions, including Chronic Obstructive Pulmonary Disease (COPD), asthma, and chronic heart failure, and can lead to severe outcomes, such as pneumonia, hospitalization, and death.Arexy’s turnover fell 57% in the first quarter (Q1) of 2025 to £78 million ($105 million) due to lower demand. The company pegged the decline in sales within the U.S. partly to a more limited recommendation from the Advisory Committee on Immunization Practices for individuals aged 60 to 74.On Stocktwits, retail sentiment around GSK stayed unmoved within ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1366/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_8_31_53_AM_png_fd0d117e35.webp" alt="GSK's Sentiment Meter and Message Volume as of 8:30 a.m. ET on July 14, 2025 | Source: Stocktwits" width="1366" height="130"><figcaption>GSK's Sentiment Meter and Message Volume as of 8:30 a.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>NYSE-listed shares of GSK are up by 13% this year but down by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/synopsys-ansys-35-billion-deal-reportedly-gets-china-conditional-approval/ch8Bx5yR5V8">Synopsys-Ansys’ $35B Deal Reportedly Gets China’s Conditional Approval Days Before Closure Deadline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: £1= $1.35)

GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance

A decision by the FDA on the new submission is expected in the first half of 2026.

Fidelity Covington Trust - Fidelity Women's Leadership

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

FDWM
Fidelity Covington Trust - Fidelity Women`s Leadership ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FDWM News

FDWMFidelity Covington Trust - Fidelity Women`s Leadership ETF